Published 2026-06-23
The heaviest concentration of event risk in mid-June left high-yield spreads flat and corporate buybacks elevated, as markets look to a packed calendar of US economic data in the coming weeks.
At a glance
This weekNick Timiraos: Three Things I’m Watching at Kevin Warsh’s First Fed Meeting
Model stance61% cash · 17 positions
Recent Events
The heaviest concentration of event risk landed on June 17, when the first FOMC meeting under Chair Warsh coincided with a steady Bank of Japan decision, just a week after the ECB became the first major central bank to raise rates since the inflation resurgence. A US CPI release earlier in the window had framed that policy turn. Across the credit landscape, mid-June dividend cuts from BDCs FSK and NMFC hinted at pockets of strain, yet high-yield spreads remained flat. Geopolitical friction at the G7 summit and a Fed communication tone that measured a low 10 out of 100 completed the picture, leaving markets to absorb a dense mix of signals.
Macro & policy
2026-06-17Nick Timiraos: Three Things I’m Watching at Kevin Warsh’s First Fed Meeting
2026-06-17G7 summit live: Trump says US will go 'back to shooting' at Iran if he doesn't like the final deal
2026-06-18Fed Communication: 10/100 (LOW)
2026-06-11ECB Becomes First Major Central Bank to Raise Interest Rates Since Inflation Resurgence
Credit & corporate
2026-06-17FSK regular dividend cut: 0.48 → 0.42 (-12.5%)
2026-06-16NMFC regular dividend cut: 0.32 → 0.25 (-21.9%)
2026-06-18HY OAS Weekly: FLAT → hold cash
On the calendar
2026-06-17Bank of Japan Monetary Policy Meeting
2026-06-17FOMC monetary policy decision
2026-06-10Consumer Price Index (CPI) release
Notable news
2026-06-178-K Other Events
2026-06-10BDX (Becton Dickinson & Company)
2026-06-10B Braun Medical Inc
Upcoming Events
The calendar ahead is built around a dense run of US data, with the PCE inflation report and the GDP release both hitting on June 25, followed by the June employment report on July 2 and the CPI and PPI prints in the middle of the month. That macro spine is interrupted by a market-structure event on July 6, when the fast-entry window opens for SpaceX to join the Nasdaq-100, a catalyst that often concentrates liquidity demands and index-repricing flows. A steadier pulse comes from the PBOC’s loan prime rate fixings on June 22 and July 20, while the earnings season begins to build, with over 350 reports queued up and early reporters such as KBH and LZB arriving in the opening days.
2026-06-22● PBOC Loan Prime Rate (LPR) fixing (CN)
2026-06-25● Personal Income & Outlays (PCE) release (US)
2026-06-25● Gross Domestic Product (GDP) release (US)
2026-07-02● Employment Situation (Nonfarm Payrolls) release (US)
2026-07-06● SpaceX Nasdaq-100 fast-entry window (US)
2026-07-14● Consumer Price Index (CPI) release (US)
2026-07-15● Producer Price Index (PPI) release (US)
2026-07-17● Monthly options expiration (OpEx) (US)
2026-07-20● PBOC Loan Prime Rate (LPR) fixing (CN)
Plus 353 corporate earnings reports scheduled in the window.
Macro Projections
The near-term outlook is range-bound at high confidence, resting on a risk distribution rather than a point forecast. High-yield credit spreads have tightened to 266 basis points while the equity volatility gauge remains low, but there is an uncomfortable armament behind that calm: a hot CPI reading, sticky dollar-yen, and stress indicators in business-development companies push the distribution’s skew out, exposing tail risk. The binary window set by Iran ceasefire talks and the June 25 PCE release will resolve in short order, leaving the tactical picture anchored to how those shocks ripple through already-elevated hedging signals. Where that condensed event risk clears, the cyclical months-to-quarters horizon shifts to an improving lean, held with moderate confidence. The credit cycle is early and spreads are contracting; the Federal Reserve stays on hold as sticky inflation suppresses rate cuts, which makes a disorderly carry unwind a roughly 32% probability tail, alongside the risk of a fresh EM credit crisis. The base case is a managed reflation grind that channels capital toward real assets—gold, inflation-protected bonds, energy—and away from long-duration equities and nominal bonds, a path that is better captured by credit-spread trajectories than by equity indices, even though the structural carry-unwind model injects regime-shift uncertainty. That cyclical favour for real assets aligns with a secular, multi-year lean that also reads as improving, but here confidence drops to low. The underlying mechanism is the post-2020 monetary regime: structurally higher inflation, fiscal dominance, and de-dollarisation push the most likely long-term path toward financial repression, where sustained negative real rates systematically penalise nominal bonds and cash-heavy portfolios.
Cyclical ▬●●● expires Sep 20, 2026
HY OAS remains range-bound between 2.5% and 3.0% through September 22, 2026, the headline credit market stays calm despite subsurface stress signals.
This is the muddle-through scenario. HY OAS has been tightly range-bound at 2.63–2.80% across the 14-day trajectory window.
Near term ▲●●● expires Jul 22, 2026
The CCC/BB reading ends July 2026 above 2.70, continuing its accelerating widening trajectory.
Cross-validated across three domains. (1) Credit trajectory: the CCC/BB reading trail shows 0.73 → 1.26 → 1.59 → 2.44 with direction "accelerating_positive", the widest and fastest-moving eight-period sequence in the series.
Secular ▲●●● expires Jun 22, 2027
Developed ex-US equities outperform US equities by more than 300 basis points over the 12 months ending June 22, 2027, as measured by the earnings-yield gap compression.
Cross-validated across valuation, positioning, and carry-risk domains. (1) Valuation anchor: US earnings yield 3.69% vs developed ex-US 5.37% and EM 5.51%, a 168–182 bp structural gap.
Cyclical ▼●●● expires Dec 19, 2026
The carry-unwind model's p_disorderly_unwind rises above 0.40 by December 22, 2026, from the current 0.323.
The model's explanatory tags, "usdjpy breached 160," "jgb proximate 285," "fx vol elevated," "carry positioning extreme", describe a carry complex already under strain. COT positioning extremes (UST 2Y short, JPY short, EUR short ) are one-directional and vulnerable to a reversal.
Positioning
With high-yield credit spreads near 2.63%, the book enters a calm credit regime and sizes every holding from its screening-kernel composite score—a blend of modelled upside drift against drawdown probability—so that conviction directly drives position weights. The highest-scoring names therefore command the largest equity allocations, keeping the portfolio concentrated where the modelled risk-reward trade-off appears most attractive. Layered alongside this conviction framework are several historically documented structural mechanisms—oil supply shocks feeding headline CPI, commodity production losses lifting agricultural prices, and yen carry unwinds pressuring global equities—each discounted by what the market already prices and weighed by its own base rate and prior misses, serving as a risk-awareness overlay rather than a set of predictions.
| Name | Conviction score | Modelled drift |
|---|
| SSRM | 4.78 | +4.8% |
| STRO | 4.78 | +4.5% |
| JAZZ | 4.72 | +4.7% |
| LQDA | 4.62 | +5.0% |
| IAG | 4.57 | +4.9% |
| NVT | 4.55 | +4.5% |
oil supply shock headline cpi → headline CPI ▲ · 86% base rate · n=7 · 60% pricedcommodity production loss → agricultural commodity ▲ · 80% base rate · n=5 · 40% pricedyen carry unwind risk off → global equities ▼ · 55% base rate · n=38 · 20% priced
Model Portfolio
The model portfolio sits heavily in cash, keeping more than half its capital in money-market instruments as dry powder for staged deployment. The rest of the book is tilted toward real assets, with a structural allocation to gold and inflation-linked Treasuries, while a modest quality-equity sleeve rides the AI capex cycle.
Cash 61.0%Inflation-linked 10.0%Gold & metals 8.0%Equity 5.0%
| Name | Weight | Thesis |
|---|
| Cash · 61.0% |
| Money Market | 61.0% | money-market / cash |
| Inflation-linked · 10.0% |
| SCHP | 4.9% | inflation-linked Treasuries |
| VTIP | 2.9% | inflation-linked Treasuries |
| LTPZ | 2.2% | inflation-linked Treasuries |
| Gold & metals · 8.0% |
| IAU | 4.8% | gold / precious-metals |
| GDX | 1.8% | gold / precious-metals |
| FNV | 0.6% | gold / precious-metals |
| WPM | 0.6% | gold / precious-metals |
| SLV | 0.2% | gold / precious-metals |
| Equity · 5.0% |
| QUAL | 2.6% | global quality equity |
| SSRM | 0.7% | global quality equity |
| STRO | 0.6% | global quality equity |
| JAZZ | 0.4% | global quality equity |
| LQDA | 0.3% | global quality equity |
| IAG | 0.2% | global quality equity |
| NVT | 0.1% | global quality equity |
| ICCC | 0.1% | global quality equity |
Position notes
SSRM 0.7%
Full research note
SSR Mining explores and develops precious metal properties in Turkey and the Americas.
Bull case · If geopolitical tensions (Iran/Hormuz) persist or escalate, gold and silver may rally, lifting SSR Mining’s cash flows and share price. The company’s relatively low AISC and clean balance sheet could attract safe-haven flows in a prolonged inflation/repression regime.
Bear case · A de-escalation of the Iran crisis would remove the geopolitical risk premium from precious metals, exposing SSR Mining’s highly cyclical earnings. our model's negative edge suggests the stock is overvalued relative to its fundamentals, and technical indicators (reversal in 3-month momentum, declining volume) hint at fading investor interest.
Key risks• Commodity price volatility driven by geopolitical events, particularly a ceasefire that deflates gold/silver premiums.
• Operational risks including cost inflation and mine-specific disruptions, which could compress margins.
• Lack of near-term catalysts or proprietary research coverage limits conviction.
• Mid-cap status in a sector dominated by mega-cap miners, leading to limited institutional attention and liquidity risk in risk-off environments.
• our model's consistently negative edge across horizons signals a systematic headwind.
STRO 0.6%
Full research note
Clinical-stage biopharma developing ADCs with proprietary cell-free synthesis platform, pre-revenue and restructuring.
Bull case · Positive STRO-004 readout in mid‑2026 could validate the platform, trigger a lucrative partnership or buyout, and re‑rate the stock from its current ~$30 to the analyst target of $47+, with long‑term optionality from a broad ADC pipeline. The recent $110M raise and Astellas milestone provide cash through 2028, buying time for additional catalysts.
Bear case · If STRO‑004 data fails to differentiate in the crowded Tissue Factor ADC space, the stock could lose 80%+ as all platform value evaporates. Even with extended cash runway, the burn rate (~$50M/quarter) and lack of revenue force eventual dilution or restructuring. The 250% six‑month price surge and subsequent pullback suggest sentiment has already priced in some good news, leaving no margin for disappointment.
Key risks• Binary clinical risk: STRO-004 Phase 1 data in mid‑2026 is make‑or‑break; failure would likely wipe out the company’s value.
• Competitive landscape: The Tissue Factor ADC space is crowded with well‑funded players, and Sutro’s candidate may not show a meaningful advantage.
• Financing and dilution: Despite the recent raise, ongoing cash burn will require additional capital by 2028, likely at dilutive levels.
• Micro‑cap illiquidity: The stock’s small float and extended technical position amplify drawdowns during market stress (e.g., carry‑unwind).
• Macro sensitivity: As a risk‑on, small‑cap biotech, STRO would be disproportionately sold off in any geopolitical or rate‑driven risk‑off event.
JAZZ 0.4%
Full research note
The dominant 30-day narrative for Jazz Pharmaceuticals (JAZZ) is a sharp tug-of-war between exceptional commercial execution and a sudden clinical setback. In early May 2026, Jazz delivered a blowout Q1 earnings report with record revenue of $1.07 billion (+19% YoY) and an adjusted EPS of $6.34 that crushed the $4.66 consensus, prompting a UBS upgrade to a $307 price target. However, sentiment took a severe hit on June 12 when the Phase 3 LAGOON trial for Zepzelca in second-line small cell lung cancer failed to meet its primary endpoint. The market is now rapidly re-evaluating the company's oncology expansion pipeline while pivoting focus to the upcoming August 25, 2026, PDUFA date for zanidatamab (Ziihera).
Bull case · The bull case anchors on Jazz's highly cash-generative commercial portfolio and successful lifecycle management. Xywav continues to successfully cannibalize legacy Xyrem, shielding the sleep franchise from high-sodium generic erosion, while Epidiolex has comfortably surpassed a $1 billion annualized run-rate with 15% YoY growth in Q1 2026. Furthermore, the upcoming August 2026 PDUFA date for zanidatamab in 1L HER2+ GEA offers a near-term, de-risked catalyst to solidify the company's rare oncology footprint.
Bear case · The bear case is heavily fueled by the June 12, 2026, failure of the Phase 3 LAGOON trial for Zepzelca, which severely damages the drug's label expansion prospects and calls into question the ROI of Jazz's oncology acquisitions. Bears argue that despite strong current cash flows, Jazz's heavy reliance on the oxybate franchise leaves it vulnerable to intensifying generic competition and ongoing patent litigation, meaning any pipeline stumbles carry outsized multiple-compression risk.
Key risks• Clinical execution risk following the high-profile Phase 3 LAGOON trial failure for Zepzelca.
• Intensifying generic competition for the legacy Xyrem (high-sodium oxybate) franchise.
• Regulatory binary risk heading into the August 25, 2026, PDUFA date for zanidatamab.
• Ongoing patent litigation and settlements surrounding the broader sleep medicine portfolio.
LQDA 0.3%
Full research note
Biopharma commercializing inhaled treprostinil for PAH/PH-ILD; regulatory moat from FDA approval.
Bull case · The stock's accelerating price trend and model allocation signal suggest an upcoming catalyst—possibly pipeline progress or a partnership—that could drive substantial upside. Healthcare sector leadership provides a tailwind, and the mid‑cap size permits 10–30× compounding if execution succeeds.
Bear case · Without fundamental visibility, the momentum could reverse sharply. Biotech cohorts show deeply negative operating margins and a poor rule‑of‑40, indicating the sector is burning cash. Macro threats—Iran tensions, carry unwind—could crush risk appetite and illiquid mid‑cap names, and LQDA has no earnings or news catalysts to defend its valuation.
Key risks• Binary biotech risk from undisclosed pipeline assets.
• High volatility and drawdown potential, typical of small/mid‑cap healthcare.
• Lack of any recent news or fundamental catalysts leaves the stock exposed to pure sentiment shifts.
• Macro geopolitical escalation (Iran/Hormuz) could trigger a broad risk‑off event.
SLV 0.2%
Full research note
Trust holding physical silver to reflect silver price performance.
Bull case · The strongest bullish sentiment anchors on the unprecedented industrial demand wave from AI infrastructure and newer TOPCon solar panels, which are structurally increasing silver intensity per unit. Proponents argue that with mine production severely constrained and consecutive years of global supply deficits, the current macro-driven selloff offers a generational entry point before physical shortages force a violent repricing.
Bear case · Bears point to the immediate macroeconomic reality: a structurally higher US dollar and elevated real yields under a hawkish Fed are crushing the monetary premium of precious metals. This has triggered massive volatility and forced liquidations, with the "safe haven" narrative unwinding rapidly amid potential Middle East de-escalation, leaving silver vulnerable to further downside if industrial demand softens in a recession.
Key risks• Sustained hawkishness from the Federal Reserve driving real yields higher and accelerating ETF redemptions.
• A durable resolution to the Iran-Hormuz conflict draining the geopolitical safe-haven premium from precious metals.
• Technological substitution or "thrifting" in solar panel manufacturing reducing the silver intensity per cell.
• Intense fee competition from lower-cost physical silver ETFs eroding SLV's market share among retail investors.
IAG 0.2%
Full research note
IAMGOLD is a gold mining company operating mines in the Americas and West Africa.
Bull case · The bullish narrative centers on IAMGOLD's flawless execution at Côté Gold, which has achieved its 36,000 tonnes-per-day nameplate capacity and drove record revenues exceeding $1 billion in Q1 2026. Investors are cheering management's disciplined capital allocation, highlighted by the recent repayment of its remaining $130 million 2nd Lien Term Loan and a massive 57-million share buyback program that provides a hard floor under the stock price.
Bear case · Bears point to the fragility of the gold macro environment, warning that any Iran-US peace deal or Hormuz de-escalation could trigger a sharp pullback in bullion prices, exposing IAMGOLD's still-elevated consolidated All-In Sustaining Costs (AISC) of $1,900/oz. Furthermore, a recent cluster of insider selling—with $855K unloaded by three directors in late February—signals potential internal skepticism about the durability of the current valuation peak.
Key risks• Geopolitical de-escalation (e.g., an Iran peace deal) triggering a sudden collapse in safe-haven gold premiums.
• Sector-wide cost inflation in labor and energy compressing margins if gold prices normalize.
• Insider selling cluster by directors signaling a potential near-term valuation ceiling.
• Execution risks related to the upcoming Côté Gold conveyor belt replacement and phase-out of the temporary crushing circuit.
NVT 0.1%
Full research note
The dominant 30-day narrative for nVent Electric (NVT) centers on its explosive emergence as a premier "picks and shovels" beneficiary of the AI liquid cooling supercycle. Following a massive Q1 2026 earnings blowout on May 1—featuring 53% revenue growth and a 76% surge in its Systems Protection segment—the market is hyper-focused on the company's record $2.6 billion backlog. Investors are aggressively repricing NVT from a legacy electrical components manufacturer to a critical AI infrastructure pure-play.
Bull case · The sentiment-driven bull case is fueled by undeniable fundamental momentum and a sharply bullish R19-T10 revision-momentum signal, with 11 upward analyst revisions and zero downgrades (net +100%) over the last 30 days. A June 9 outperform initiation by Bernstein further amplified enthusiasm, highlighting nVent's advanced cooling distribution unit (CDU) technology and its ability to capture outsized market share as hyperscalers transition from air to liquid cooling architectures.
Bear case · The bear narrative focuses on a stretched valuation (38x P/E) that leaves no room for execution missteps, compounded by a glaring insider selling cluster. Executives, including the President and EVPs, have offloaded nearly $16 million in stock over the last 90 days into the post-earnings rally, raising concerns about a potential near-term top while the company navigates $80 million in projected 2026 tariff headwinds.
Key risks• Insider selling cluster with top executives aggressively taking profits following the Q1 earnings surge.
• Multiple compression risk as structurally higher real rates penalize long-duration industrial compounders.
• Intense competitive pressure from Vertiv and Schneider Electric in the hyperscale liquid cooling market.
• Margin vulnerability to $80 million in projected 2026 tariff costs if pricing power wanes.
ICCC 0.1%
Full research note
ImmuCell sells antibody-based product First Defense to prevent calf scours in cattle.
Bull case · The company generates decent free cash flow (FCF margin 32.8% in Q1 2026 on revenue of USD 10.4M) which could support debt servicing in the near term. A successful expansion of the product pipeline, a strategic acquisition, or a return to growth in the dairy industry could provide upside. At current levels, the stock may appear cheap on a P/E basis, but this is illusory without a catalyst.
Bear case · The high debt load relative to cash (net cash negative USD 5.96M) poses refinancing risk in an elevated interest-rate environment. The company's product line is concentrated in dairy calves, leaving it vulnerable to sector-specific downturns. With no sell-side coverage, no insider buying, and no scheduled catalysts, the stock is likely to languish as a micro-cap value trap, with illiquidity amplifying any downside.
Key risks• High financial leverage (net cash negative USD 5.96M) and refinancing risk in a higher-for-longer rate regime.
• Extreme micro-cap illiquidity that can cause explosive downside on any adverse event.
• Product concentration; dependence on the dairy industry and lack of pipeline diversification.
• No analyst coverage or institutional sponsorship, leaving the stock in a chronic undervaluation discount.
• Negative net cash position limits financial flexibility and increases vulnerability to economic downturns.
Track Record
The very early track record covers only eight days of evaluated ideas, so any conclusions must be considered provisional. Across 233 short-term signals with a one-day horizon, the hit rate has edged just above even and the average alpha is a modest 0.3%, though raw returns have remained essentially flat. Outcomes for the one-week, four-week, and three-month horizons are not yet mature—the first signals in those windows are still gathering toward their evaluation dates.
Macro forecasts: 85 written down with explicit horizons and being tracked; each will be graded against what actually happens as its horizon arrives.
Positions, conflicts & disclosures
DISCLAIMER — NOT INVESTMENT ADVICE (DECISION-LINKED)
This publication provides GENERAL and IMPERSONAL commentary and analysis on a regular schedule. The same content is provided to every subscriber. It is NOT investment advice, is NOT tailored to any individual, and does NOT account for your personal financial situation, objectives, or risk tolerance.
This post reports (1) a rules-based MODEL portfolio — target weights produced by an automated system's published rules, identical for all readers — and (2) DECISION-LINKED activity: how that affiliated automated system actually implemented, or has queued to implement, those rules in accounts belonging to the publication's operator. Model weights are not an account statement; the decision-linked positions and pending orders are REAL and belong to accounts affiliated with this publication's operator. We publish them for transparency on a fixed schedule under our Trading & Publication Policy [link] — not as a recommendation that any security or strategy is suitable for you. Because the publisher and/or operator hold or intend to establish positions in the securities discussed, a conflict of interest exists and our interests may differ from yours.
Nothing here is a recommendation to buy, sell, or hold any security for you specifically. Investing involves risk, including loss of principal. Past performance — model or actual — does not guarantee future results.
[Publisher LLC] is not a registered investment adviser and does not provide individualized investment advice. Consult a licensed professional before making any investment decision. See full disclosures, methodology, and our Trading & Publication Policy at [link].
POSITIONS DISCLOSURE: this is a hypothetical, rules-based model portfolio, not a statement of any individual's actual account; the publisher and/or author may hold positions in one or more of the securities listed.
CONFLICT OF INTEREST: because the publisher and/or author may hold listed securities, a conflict of interest exists and could benefit from price movements; the publisher receives no compensation for featuring any security, and this impersonal model illustration is not personalized investment advice or a solicitation to transact.
MICRO-CAP CAVEAT: some listed names are micro-capitalization securities held at small model weights; micro-caps carry elevated liquidity and volatility risk and are unsuitable for short-term trading — the small weights reflect that risk, and nothing here is a recommendation to scalp or rapidly trade thinly-traded securities.
Intended transactions: the affiliated automated system has open or queued target allocations in the following securities discussed here: FNV, GDX, IAG, IAU, ICCC, JAZZ, LQDA, LTPZ, NVT, QUAL, SCHP, SLV, SSRM, STRO, VTIP, WPM. These are real pending orders or model target weights in accounts belonging to the publication's operator, disclosed for transparency under our Trading & Publication Policy [link] — not a recommendation, and our interests may differ from yours.
